Ovarian cancer

Biotargets of Cancer in Current Clinical Practice

Volumn , Issue , 2012, Pages 381-401

  Oribabor, Jessica Wangui ^a   Ambrosio, Allison ^a   Castro, Cesar M ^a   Birrer, Michael J ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84890850119     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-61779-615-9_14     Document Type: Chapter

References (101)

1. Fleming GF, Ronnett BM, Seidman J, Zaino RJ, Rubin SC. Epithelial Ovarian Cancer. In: Markman M, Barakat RR, Randall ME, editors. Principles and practice of gynecologic oncology. 5th ed. Baltimore: Lippincott Williams & Wilkins; 2009. p. 763-835.
2. Bast Jr.RC, Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer. 2009;9:415-28.
3. Hennessy BT, Coleman RL, Markman M. Ovarian cancer. Lancet. 2009;374:1371-82.
4. Helzlsouer KJ, Bush TL, Alberg AJ, Bass KM, Zacur H, Comstock GW. Prospective study of serum CA-125 levels as markers of ovarian cancer. JAMA. 1993;269:1123-6.
5. Jellum E, Andersen A, Lund-Larsen P, Theodorsen L, Orjasaeter H. Experiences of the Janus Serum Bank in Norway. Environ Health Perspect. 1995;103 Suppl 3:85-8.
6. Hellstrom I, Raycraft J, Hayden-Ledbetter M, et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res. 2003;63:3695-700.
7. Rosen DG, Wang L, Atkinson JN, et al. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol. 2005;99: 267-77.
8. Fujirebio Diagnostics I. HE4 EIA [package insert]. Malvern, PA; 2008.
9. Campbell S, Bhan V, Royston P, Whitehead MI, Collins WP. Transabdominal ultrasound screening for early ovarian cancer. BMJ. 1989;299:1363-7.
10. Van Nagell Jr.JR, DePriest PD, Reedy MB, et al. The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer. Gynecol Oncol. 2000;77:350-6.
11. Guerriero S, Alcazar JL, Ajossa S, et al. Transvaginal color Doppler imaging in the detection of ovarian cancer in a large study population. Int J Gynecol Cancer. 2010;20:781-6.
12. Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet. 2002;359:572-7.
13. Giljohann DA, Mirkin CA. Drivers of biodiagnostic development. Nature. 2009;462:461-4.
14. Cane P, Azen C, Lopez E, Platt LD, Karlan BY. Tumor marker trends in asymptomatic women at risk for ovarian cancer: relevance for ovarian cancer screening. Gynecol Oncol. 1995;57:240-5.
15. Skates SJ, Menon U, MacDonald N, et al. Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women. J Clin Oncol. 2003;21:206s-10.
16. Lu KH, Skates SJ, Bevers TB, et al. A prospective U.S. ovarian cancer screening study using the risk of ovarian cancer algorithm (ROCA). J Clin Oncol. 2010;28(suppl). abstr 5003.
17. Menon U, Gentry-Maharaj A, Hallett R, et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol. 2009;10:327-40.
18. Nolen B, Velikokhatnaya L, Marrangoni A, et al. Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass. Gynecol Oncol. 2010;117:440-5.
19. Jacob F, Meier M, Caduff R, et al. No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting. Gynecol Oncol. 2011;121:487-91.
20. Andersen MR, Goff BA, Lowe KA, et al. Use of a Symptom Index, CA125, and HE4 to predict ovarian cancer. Gynecol Oncol. 2010;116:378-83.
21. Moore RG, Miller MC, Disilvestro P, et al. Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass. Obstet Gynecol. 2011;118:280-8.
22. Van Gorp T, Cadron I, Despierre E, et al. HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm. Br J Cancer. 2011;104:863-70.
23. Moore RG, McMeekin DS, Brown AK, et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol. 2009;112:40-6.
24. Zhang Z, Chan DW. The road from discovery to clinical diagnostics: lessons learned from the first FDA-cleared in vitro diagnostic multivariate index assay of proteomic biomarkers. Cancer Epidemiol Biomarkers Prev. 2010;19:2995-9.
25. Ueland FR, Desimone CP, Seamon LG, et al. Effectiveness of a multivariate index assay in the preoperative assessment of ovarian tumors. Obstet Gynecol. 2011;117:1289-97.
26. Holschneider C, Berek J. Ovarian cancer: epidemiology, biology and prognostic factors. Semin Surg Oncol. 2000;19 (1):3-10.
27. Bristow RE, Puri I, Chi DS. Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. Gynecol Oncol. 2009;112:265-74.
28. Kaku T, Ogawa S, Kawano Y, et al. Histological classification of ovarian cancer. Med Electron Microsc. 2003;36:9-17.
29. Kobel M, Kalloger SE, Santos JL, Huntsman DG, Gilks CB, Swenerton KD. Tumor type and substage predict survival in stage I and II ovarian carcinoma: insights and implications. Gynecol Oncol. 2010; 116:50-6.
30. Thigpen T, Brady MF, Omura GA, et al. Age as a prognostic factor in ovarian carcinoma. The Gynecologic Oncology Group experience. Cancer. 1993;71:606-14.
31. Omura GA, Brady MF, Homesley HD, et al. Longterm follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. J Clin Oncol. 1991;9: 1138-50.
32. Cooper BC, Sood AK, Davis CS, et al. Preoperative CA 125 levels: an independent prognostic factor for epithelial ovarian cancer. Obstet Gynecol. 2002;100: 59-64.
33. Gadducci A, Cosio S, Fanucchi A, Negri S, Cristofani R, Genazzani AR. The predictive and prognostic value of serum CA 125 half-life during paclitaxel/platinum-based chemotherapy in patients with advanced ovarian carcinoma. Gynecol Oncol. 2004;93:131-6.
34. Rustin GJ. The clinical value of tumour markers in the management of ovarian cancer. Ann Clin Biochem. 1996;33(Pt 4):284-9.
35. Meyer T, Rustin GJ. Role of tumour markers in monitoring epithelial ovarian cancer. Br J Cancer. 2000;82:1535-8.
36. Verheijen RH, von Mensdorff-Pouilly S, van Kamp GJ, Kenemans P. CA 125: fundamental and clinical aspects. Semin Cancer Biol. 1999;9:117-24.
37. Riedinger JM, Wafflart J, Ricolleau G, et al. CA 125 half-life and CA 125 nadir during induction chemotherapy are independent predictors of epithelial ovarian cancer outcome: results of a French multicentric study. Ann Oncol. 2006;17:1234-8.
38. Diaz-Montes Ta BRE. Clinical predictors of outcome in epithelial ovarian carcinoma. In: Levenback C, Sood, AK, Lu, KH, Coleman, R, editors. Prognostic and predictive factors in gynecologic cancers. Houston, TX: Informa; 2007. p. 9.
39. Skirnisdottir I, Sorbe B, Karlsson M, Seidal T. Prognostic importance of DNA ploidy and p53 in early stages of epithelial ovarian carcinoma. Int J Oncol. 2001;19:1295-302.
40. Havrilesky L, Darcy M, Hamdan H, et al. Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2003;21:3814-25.
41. Rose SL. TP53/p53 as a prognostic factor. In: Levenback C, Sood AK, Lu KH, Coleman R, editors. Prognostic and predictive factors in gynecologic cancers. Houston, TX: Informa; 2007. p. 45-61.
42. Tothill RW, Tinker AV, George J, et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res. 2008;14:5198-208.
43. Goff BA, Ries JA, Els LP, Coltrera MD, Gown AM. Immunophenotype of ovarian cancer as predictor of clinical outcome: evaluation at primary surgery and second-look procedure. Gynecol Oncol. 1998;70: 378-85.
44. Allan LA, Campbell MK, Milner BJ, et al. The significance of p53 mutation and over-expression in ovarian cancer prognosis. Int J Gynecol Cancer. 1996;6:483-90.
45. Tachibana M, Watanabe J, Matsushima Y, et al. Independence of the prognostic value of tumor suppressor protein expression in ovarian adenocarcinomas: a multivariate analysis of expression of p53, retinoblastoma, and related proteins. Int J Gynecol Cancer. 2003;13:598-606.
46. Dogan E, Saygili U, Tuna B, et al. p53 and mdm2 as prognostic indicators in patients with epithelial ovarian cancer: a multivariate analysis. Gynecol Oncol. 2005;97:46-52.
47. Geisler JP, Geisler HE, Wiemann MC, Givens SS, Zhou Z, Miller GA. Quantification of p53 in epithelial ovarian cancer. Gynecol Oncol. 1997;66: 435-8.
48. van der Zee AG, Hollema H, Suurmeijer AJ, et al. Value of P-glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas. J Clin Oncol. 1995;13:70-8.
49. Sagarra RA, Andrade LA, Martinez EZ, Pinto GA, Syrjanen KJ, Derchain SF. P53 and Bcl-2 as prognostic predictors in epithelial ovarian cancer. Int J Gynecol Cancer. 2002;12:720-7.
50. Sheridan E, Silcocks P, Smith J, Hancock BW, Goyns MH. P53 mutation in a series of epithelial ovarian cancers from the U.K., and its prognostic significance. Eur J Cancer. 1994;30A:1701-4.
51. Mano Y, Kikuchi Y, Yamamoto K, et al. Bcl-2 as a predictor of chemosensitivity and prognosis in primary epithelial ovarian cancer. Eur J Cancer. 1999;35:1214-9.
52. Hashiguchi Y, Tsuda H, Inoue T, Nishimura S, Suzuki T, Kawamura N. Alteration of cell cycle regulators correlates with survival in epithelial ovarian cancer patients. Hum Pathol. 2004;35:165-75.
53. Marks JR, Davidoff AM, Kerns BJ, et al. Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res. 1991;51:2979-84.
54. Bali A, O'Brien PM, Edwards LS, Sutherland RL, Hacker NF, Henshall SM. Cyclin D1, p53, and p21Waf1/Cip1 expression is predictive of poor clinical outcome in serous epithelial ovarian cancer. Clin Cancer Res. 2004;10:5168-77.
55. Ferrandina G, Fagotti A, Salerno MG, et al. p53 overexpression is associated with cytoreduction and response to chemotherapy in ovarian cancer. Br J Cancer. 1999;81:733-40.
56. Shahin MS, Hughes JH, Sood AK, Buller RE. The prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma. Cancer. 2000;89:2006-17.
57. Baekelandt M, Kristensen GB, Nesland JM, Trope CG, Holm R. Clinical significance of apoptosis-related factors p53, Mdm2, and Bcl-2 in advanced ovarian cancer. J Clin Oncol. 1999;17:2061.
58. Marx D, Meden H, Ziemek T, Lenthe T, Kuhn W, Schauer A. Expression of the p53 tumour suppressor gene as a prognostic marker in platinum-treated patients with ovarian cancer. Eur J Cancer. 1998;34: 845-50.
59. Hartmann LC, Podratz KC, Keeney GL, et al. Prognostic significance of p53 immunostaining in epithelial ovarian cancer. J Clin Oncol. 1994;12:64-9.
60. Nielsen JS, Jakobsen E, Holund B, Bertelsen K, Jakobsen A. Prognostic significance of p53, Her-2, and EGFR overexpression in borderline and epithelial ovarian cancer. Int J Gynecol Cancer. 2004; 14:1086-96.
61. Okuda T, Otsuka J, Sekizawa A, et al. p53 mutations and overexpression affect prognosis of ovarian endometrioid cancer but not clear cell cancer. Gynecol Oncol. 2003;88:318-25.
62. Niwa K, Itoh M, Murase T, et al. Alteration of p53 gene in ovarian carcinoma: clinicopathological correlation and prognostic significance. Br J Cancer. 1994;70:1191-7.
63. Smith-Sorensen B, Kaern J, Holm R, Dorum A, Trope C, Borresen-Dale AL. Therapy effect of either paclitaxel or cyclophosphamide combination treatment in patients with epithelial ovarian cancer and relation to TP53 gene status. Br J Cancer. 1998;78:375-81.
64. Leitao Jr.MM, Boyd J, Hummer A, et al. Clinicopathologic analysis of early-stage sporadic ovarian carcinoma. Am J Surg Pathol. 2004;28: 147-59.
65. Fallows S, Price J, Atkinson RJ, Johnston PG, Hickey I, Russell SE. P53 mutation does not affect prognosis in ovarian epithelial malignancies. J Pathol. 2001;194:68-75.
66. Schuyer M, van der Burg ME, Henzen-Logmans SC, et al. Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2. Br J Cancer. 2001;85:1359-67.
67. Wang Y, Helland A, Holm R, et al. TP53 mutations in early-stage ovarian carcinoma, relation to longterm survival. Br J Cancer. 2004;90:678-85.
68. Wang Y, Kringen P, Kristensen GB, et al. Effect of the codon 72 polymorphism (c.215G>C, p.Arg72Pro) in combination with somatic sequence variants in the TP53 gene on survival in patients with advanced ovarian carcinoma. Hum Mutat. 2004;24:21-34.
69. Reles A, Wen WH, Schmider A, et al. Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer. Clin Cancer Res. 2001;7:2984-97.
70. Bai L, Zhu WG. p53: Structure, Function and Therapeutic Applications. J Cancer Mol. 2006;2: 141-53.
71. Chu CS, Rubin SC. Influence of BRCA1 and BRCA2 on Ovarian Cancer Survival. In: Levenback C, Sood AK, Lu KH, Coleman R, editors. Prognostic and predictive factors in gynecologic cancers. Houston, TX: Informa; 2007. p. 15-23.
72. Secord AA, Lee PS, Darcy KM, et al. Maspin expression in epithelial ovarian cancer and associations with poor prognosis: a Gynecologic Oncology Group study. Gynecol Oncol. 2006;101:390-7.
73. Rubin SC, Benjamin I, Behbakht K, et al. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N Engl J Med. 1996;335:1413-6.
74. Aida H, Takakuwa K, Nagata H, et al. Clinical features of ovarian cancer in Japanese women with germ-line mutations of BRCA1. Clin Cancer Res. 1998;4:235-40.
75. Johannsson OT, Ranstam J, Borg A, Olsson H. Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden. J Clin Oncol. 1998;16:397-404.
76. Pharoah PD, Easton DF, Stockton DL, Gayther S, Ponder BA. Survival in familial, BRCA1-associated, and BRCA2-associated epithelial ovarian cancer. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group. Cancer Res. 1999;59:868-71.
77. Boyd J, Sonoda Y, Federici MG, et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA. 2000;283:2260-5.
78. Zweemer RP, Verheijen RH, Coebergh JW, et al. Survival analysis in familial ovarian cancer, a case control study. Eur J Obstet Gynecol Reprod Biol. 2001;98:219-23.
79. Ramus SJ, Fishman A, Pharoah PD, Yarkoni S, Altaras M, Ponder BA. Ovarian cancer survival in Ashkenazi Jewish patients with BRCA1 and BRCA2 mutations. Eur J Surg Oncol. 2001;27:278-81.
80. Ben David Y, Chetrit A, Hirsh-Yechezkel G, et al. Effect of BRCA mutations on the length of survival in epithelial ovarian tumors. J Clin Oncol. 2002; 20:463-6.
81. Buller RE, Shahin MS, Geisler JP, Zogg M, De Young BR, Davis CS. Failure of BRCA1 dysfunction to alter ovarian cancer survival. Clin Cancer Res. 2002;8:1196-202.
82. Cass I, Baldwin RL, Varkey T, Moslehi R, Narod SA, Karlan BY. Improved survival in women with BRCA-associated ovarian carcinoma. Cancer. 2003;97:2187-95.
83. Kringen P, Wang Y, Dumeaux V, et al. TP53 mutations in ovarian carcinomas from sporadic cases and carriers of two distinct BRCA1 founder mutations; relation to age at diagnosis and survival. BMC Cancer. 2005;5:134.
84. Pal T, Permuth-Wey J, Kapoor R, Cantor A, Sutphen R. Improved survival in BRCA2 carriers with ovarian cancer. Fam Cancer. 2007;6:113-9.
85. Banerjee S, Gore M. The future of targeted therapies in ovarian cancer. Oncologist. 2009;14:706-16.
86. Lose F, Nagle CM, O'Mara T, et al. Vascular endothelial growth factor gene polymorphisms and ovarian cancer survival. Gynecol Oncol. 2011;119: 479-83.
87. Horowitz NS, Penson RT, Duda DG, et al. Safety, efficacy, and biomarker exploration in a phase II study of bevacizumab, oxaliplatin, and gemcitabine in recurrent Mullerian carcinoma. Clin Ovarian Cancer Other Gynecol Malig. 2011;4:26-33.
88. Sood AK, Fletcher MS, Gruman LM, et al. The paradoxical expression of maspin in ovarian carcinoma. Clin Cancer Res. 2002;8:2924-32.
89. Mackay HJ, Oza AM. Other new targets. Int J Gynecol Cancer. 2009;19 Suppl 2:S49-54.
90. Shen GH, Ghazizadeh M, Kawanami O, et al. Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma. Br J Cancer. 2000;83:196-203.
91. Meden H, Fattahi-Meibodi A, Marx D. ELISA-based quantification of p105 (c-erbB-2, HER2/neu) in serum of ovarian carcinoma. Methods Mol Med. 2001;39:125-33.
92. Cheung TH, Wong YF, Chung TK, Maimonis P, Chang AM. Clinical use of serum c-erbB-2 in patients with ovarian masses. Gynecol Obstet Invest. 1999;48:133-7.
93. Hellstrom I, Goodman G, Pullman J, Yang Y, Hellstrom KE. Overexpression of HER-2 in ovarian carcinomas. Cancer Res. 2001;61:2420-3.
94. Meden H, Marx D, Raab T, Kron M, Schauer A, Kuhn W. EGF-R and overexpression of the oncogene c-erbB-2 in ovarian cancer: immunohistochemical findings and prognostic value. J Obstet Gynaecol (Tokyo 1995). 1995;21:167-78.
95. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer. 2001;37 Suppl 4:S9-15.
96. Elie C, Geay JF, Morcos M, et al. Lack of relationship between EGFR-1 immunohistochemical expression and prognosis in a multicentre clinical trial of 93 patients with advanced primary ovarian epithelial cancer (GINECO group). Br J Cancer. 2004;91:470-5.
97. Bookman MA, Darcy KM, Clarke-Pearson D, Boothby RA, Horowitz IR. Evaluation of monoclonal humanized anti-HER-2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER-2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol. 2003;21:283-90.
98. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007;316:1039-43.
99. Lassus H, Staff S, Leminen A, Isola J, Butzow R. Aurora-A overexpression and aneuploidy predict poor outcome in serous ovarian carcinoma. Gynecol Oncol. 2011;120:11-7.
100. Bonome T, Levine DA, Shih J, et al. A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer. Cancer Res. 2008;68:5478-86.
101. Mok SC, Bonome T, Vathipadiekal V, et al. A gene signature predictive for outcome in advanced ovarian cancer identifies a survival factor: microfibril-associated glycoprotein 2. Cancer Cell. 2009;16:521-32.